ID   KB-3-1
AC   CVCL_2088
SY   KB 3-1; KB3-1; KB31
DR   BTO; BTO:0003918
DR   CLO; CLO_0007076
DR   CLDB; cl3008
DR   BioSample; SAMN03151731
DR   ChEMBL-Cells; CHEMBL3307659
DR   ChEMBL-Targets; CHEMBL614590
DR   DSMZ; ACC-158
DR   DSMZCellDive; ACC-158
DR   GEO; GSM743501
DR   PubChem_Cell_line; CVCL_2088
DR   TOKU-E; 4096
DR   Wikidata; Q54899545
RX   PubMed=3856953;
RX   PubMed=7865904;
RX   PubMed=22118813;
RX   PubMed=24317338;
WW   https://iclac.org/wp-content/uploads/Cross-Contaminations_v12_distribution.xlsx
WW   http://www.ott.nih.gov/erma/multidrug-resistant-epidermal-carcinoma-cell-line-kb-3-1
CC   Problematic cell line: Contaminated. Parent cell line (KB) has been shown to be a HeLa derivative.
CC   Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00372.
CC   Population: African American.
CC   Doubling time: ~40 hours (DSMZ=ACC-158).
CC   Transformant: NCBI_TaxID; 333761; Human papillomavirus type 18 (HPV18).
CC   Derived from site: In situ; Uterus, cervix; UBERON=UBERON_0000002.
ST   Source(s): DSMZ; PubMed=22118813
ST   Amelogenin: X
ST   CSF1PO: 9,10
ST   D13S317: 12,13.3 (DSMZ)
ST   D13S317: 12,14 (PubMed=22118813)
ST   D16S539: 9,10
ST   D18S51: 16
ST   D19S433: 13,14
ST   D21S11: 27,28
ST   D2S1338: 17
ST   D3S1358: 15,18
ST   D5S818: 11,12
ST   D7S820: 8,12
ST   D8S1179: 12,13
ST   FGA: 21
ST   Penta D: 8,15
ST   Penta E: 7,17
ST   TH01: 7
ST   TPOX: 8,12
ST   vWA: 16,18
DI   NCIt; C27677; Human papillomavirus-related cervical adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0372 ! KB
SX   Female
AG   30Y6M
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 25
//
RX   PubMed=3856953; DOI=10.1007/BF01534700;
RA   Akiyama S.-i., Fojo A.T., Hanover J.A., Pastan I., Gottesman M.M.;
RT   "Isolation and genetic characterization of human KB cell lines
RT   resistant to multiple drugs.";
RL   Somat. Cell Mol. Genet. 11:117-126(1985).
//
RX   PubMed=7865904;
RA   Zhang X.P., Ritke M.K., Yalowich J.C., Slovak M.L., Ho J.P.,
RA   Collins K.I., Annable T., Arceci R.J., Durr F.E., Greenberger L.M.;
RT   "P-glycoprotein mediates profound resistance to bisantrene.";
RL   Oncol. Res. 6:291-301(1994).
//
RX   PubMed=22118813; DOI=10.1016/j.canlet.2011.09.038;
RA   Krech T., Scheuerer E., Geffers R., Kreipe H.-H., Lehmann U.,
RA   Christgen M.;
RT   "ABCB1/MDR1 contributes to the anticancer drug-resistant phenotype of
RT   IPH-926 human lobular breast cancer cells.";
RL   Cancer Lett. 315:153-160(2012).
//
RX   PubMed=24317338; DOI=10.3892/or.2013.2896;
RA   Oiso S., Takayama Y., Nakazaki R., Matsunaga N., Motooka C.,
RA   Yamamura A., Ikeda R., Nakamura K., Takeda Y., Kariyazono H.;
RT   "Factors involved in the cisplatin resistance of KCP-4 human epidermoid
RT   carcinoma cells.";
RL   Oncol. Rep. 31:719-726(2014).
//